Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Every lot tested by Janoshik Analytical
Cart
Your cart is empty
Find
Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Your cart is empty
Retatrutide · GIP / GLP-1 / glucagon triple agonist
Retatrutide (LY3437943), a 39-residue acylated peptide built to engage the GIP, GLP-1 and glucagon receptors at once. Supplied as a lyophilized powder for research purposes only.
Catalog opens shortly. Leave your address and we will ping you the moment this compound is orderable.
Tested lot by lot at ≥99% purity. The Janoshik certificate for your lot is emailed with the order.
Everything Valtrax Research ships is bench material for in-vitro work. None of it is a drug, a supplement, a cosmetic, or a medical device, and none of it is intended for human or animal use, ingestion, or administration. Placing an order is your confirmation that you are a qualified researcher buying for lawful research, under every Canadian law and regulation that applies to you.
Reta — retatrutide, originally LY3437943 — pushes incretin chemistry one receptor further. Where the headline GLP-1 drugs hit one or two targets, this 39-residue acylated peptide is built to engage three at once: GIP, GLP-1, and glucagon. The fatty-acid chain is the durability piece; the three-way agonism is the design thesis.
The glucagon arm is what makes it distinct. Adding glucagon-receptor activity brings energy expenditure into play alongside the appetite and insulinotropic effects of the incretin side, so the compound is studied as a test of whether a single molecule can pull all three levers without the three working against each other.
The interesting question with Reta is balance: how potently it hits each of the three receptors and what the combined signal does that no single arm does alone. Studies parse the relative contributions of GIP, GLP-1, and glucagon activity to glycemic control, appetite, and energy expenditure, with body-weight and metabolic endpoints carrying most of the weight.
Functionally, Reta is one backbone wired to three incretin/glucagon receptors. The GLP-1 and GIP arms cover the insulinotropic and appetite-side pharmacology familiar from earlier analogues; the glucagon arm layers on a thermogenic, energy-expenditure component that the dual agonists lack.
The evidence base is unusually fast-moving for a research peptide. Coskun’s discovery paper laid out the tri-agonism, and the 2023 Jastreboff and Rosenstock Phase 2 trials read the combined receptor activity against body-weight and glycemic endpoints — the data most current work on this molecule is anchored to.
Retatrutide grew out of the multi-agonist program that followed tirzepatide. Once a GIP/GLP-1 dual agonist had proven out, the open question was whether glucagon-receptor activity could be folded into the same molecule, and LY3437943 was the candidate that carried that three-way design into testing.
Coskun’s discovery-to-proof-of-concept report established the tri-agonist profile; the trials that followed characterized it across diabetes and obesity cohorts, fixing its place in the literature as a single-peptide triple agonist.
Jastreboff, A.M. et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 389(6):514–526.
PubMedCoskun, T. et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 34(9):1234–1247.e9.
PubMedRosenstock, J. et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402(10401):529–544.
PubMedJanah, L. et al. (2019). Glucagon Receptor Signaling and Glucagon Resistance. Int J Mol Sci 20(13):3314.
PubMedFinan, B. et al. (2015). Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists. Mol Cell Endocrinol 418 Pt 1:42–54.
PubMedEvery lot is tested for identity, purity, and net content, and the certificate is emailed with the order.
Janoshik Analytical, a laboratory Valtrax does not own, runs the testing — identity by mass spectrometry, purity by RP-HPLC at ≥99%. The certificate covering the lot you receive is also emailed with your order.
Same Shelf
